Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061244 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL7588597 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL5356889 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL8906942 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL4053845 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL3207889 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL23727498 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL8906883 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL662237 | 0.98 | DUT (0.36) | DUT | |
| SCHEMBL1578618 | 0.94 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4611727-A1 | ANTI-EVAPORATIVE LIPID FORMULATIONS | University of Helsinki (FI) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024094759-A1 | ANTI-EVAPORATIVE LIPID FORMULATIONS | UNIVERSITY OF HELSINKI (FI) | 2024-05-10 | — | — | WO | disclosed |
| EP-4329730-A2 | A SPECIFIC COMBINATION OF LIPIDS AND METHODS AND USES RELATED THERETO | Helsingin Yliopisto (FI) | 2024-03-06 | — | — | EP | disclosed |
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | C4 THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022229441-A2 | A SPECIFIC COMBINATION OF LIPIDS AND METHODS AND USES RELATED THERETO | HELSINGIN YLIOPISTO (FI) | 2022-11-03 | — | — | WO | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021083949-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| EP-2183267-B1 | PROCESS FOR PREPARING 7-ALPHA-[9-(4,4,5,5,5-PENTAFLUOROTHIOPENTYL) NONYL]ESTRA-1,3,5(10)-TRIENE-3,17-BETA-DIOL | IND CHIMICA SRL (IT) | 2014-08-20 | — | — | EP | disclosed |
| EP-2183267-A2 | PROCESS FOR PREPARING 7-ALPHA-[9-(4,4,5,5,5-PENTAFLUOROTHIOPENTYL) NONYL]ESTRA-1,3,5(10)-TRIENE-3,17-BETA-DIOL | INDUSTRIALE CHIMICA S.r.l. (IT) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009013310-A2 | PROCESS FOR PREPARING 7-ALPHA-[9-(4,4,5,5,5-PENTAFLUOROTHIOPENTYL)NONYL]ESTRA-1,3,5(10)-TRIENE-3,17-BETA-DIOL | INDUSTRIALE CHIMICA S.R.L. (IT) | 2009-01-29 | — | — | WO | disclosed |
| EP-0944613-B1 | BENZOPYRAN DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2002-10-09 | — | — | EP | disclosed |
| US-6153768-A | RECEPTOR BLOCKING ANTIESTROGENS HAVING REDUCED SIDE EFFECTS | C & C RESEARCH LABORATORIES (KR) | 2000-11-28 | — | — | US | disclosed |
| EP-0944613-A1 | NOVEL BENZOPYRAN DERIVATIVES | C & C Research Laboratories (KR) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025916-A1 | NOVEL BENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1998-06-18 | — | — | WO | disclosed |
| EP-0163416-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | disclosed |
| EP-0160508-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | disclosed |
| US-4760061-A | Antioestrogenic agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-07-26 | — | — | US | disclosed |
| US-4751240-A | ANTIFERTILITY AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-06-14 | — | — | US | disclosed |
| EP-0163416-A2 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-04 | — | — | EP | disclosed |
| EP-0160508-A2 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | SMARCC1, SMARCC2, SMARCA2 | DUT 1026/4885CYP1A2 3404/4885CYP2D6 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.